SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its potential for a short squeeze, fueled by a low float and high short interest, as well as its upcoming presentation at an emerging growth conference. Community members are actively discussing the company's shift towards AI and digital infrastructure, viewing it as undervalued compared to its peers, and anticipating potential catalysts from the conference. The stock's volatile price action and history of explosive moves are also contributing to the heightened interest.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to a mixed earnings report, with concerns arising from increased spending on AI infrastructure and rising debt despite strong cloud growth and a large backlog. Community discussions revolve around whether Oracle can effectively monetize its AI investments, with some questioning the long-term viability of its strategy, while others see a buying opportunity amid the selloff. The broader market is reacting, with some fearing a potential AI bubble burst.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending following news of a national retail distribution agreement with Walmart, causing significant premarket gains. The community is actively discussing potential price targets and whether the stock can sustain its momentum, while also considering potential resistance levels. This development marks AXIL's largest retail placement, expanding access to its hearing protection products.

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Rezolute Inc

Rezolute Inc is trending downwards following the announcement of failed phase 3 trials, leading to a significant drop in stock price and triggering disappointment among investors who had anticipated positive data. The community is discussing the potential reasons for the data miss, possible future actions for the company given its cash reserves, and whether a rebound is possible, while some traders are exploring potential shorting opportunities or bottom-fishing strategies.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss a potential short squeeze, citing very high short interest and recent price movement. Community members are pointing to the difficulty in borrowing shares and high borrowing fees as further indicators of a possible squeeze. Some are expressing caution, noting the company's fundamentals and potential for a bull trap.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a potential buyout and the company's recent progress in its DM1 clinical study. Community members are debating the stock's valuation, upcoming milestones, and the potential impact of competitor data, while also analyzing recent analyst ratings and institutional ownership.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending downwards amidst analyst downgrades, most recently from BofA and JP Morgan, with concerns stemming from slowing growth in branded checkout and a perceived lack of management confidence. The community is debating the impact of buybacks, the CEO's performance, and whether the stock is undervalued or a value trap. Some traders express frustration, while others see an opportunity for long-term gains if PayPal can turn things around.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday price surge, fueled by its low float and significant volume, leading to discussions about potential short squeezes and comparisons to other recent high-flying stocks. The community is actively debating whether the run has ended or if there is potential for further gains, with some cautioning about bag holding and others anticipating after-hours momentum. Overall, traders are focused on the stock's volatile price action and potential for quick profits.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as it approaches new lows, sparking discussions about its future and potential S&P 500 exclusion. The community is debating factors like competition from Amazon, tax-loss harvesting, and the CEO's performance amid the stock's significant year-to-date decline. Some investors see a buying opportunity, while others express concerns about the company's ability to compete and innovate.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as traders debate whether its S&P 500 inclusion justifies its high valuation, with some calling it a "scam" and others predicting further gains. Community discussions revolve around potential short squeezes, the influence of interest rate cuts, and concerns about the company's fundamentals versus market hype. Despite the debate, the stock's strong upward momentum has captured significant attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare ETF (IYH) Hits New 52-Week High

IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.

<ul class="summary-bullets"><li>Prasad, who oversees gene therapies in the FDA, told Bloomberg that regulation needs to evolve as science develops.</li><li>The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. &nbsp;</li></ul>A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.Vinay Prasad, who oversees gene therapies in the U.S. Food and Drug Administration, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-31/fda-clears-way-for-faster-personalized-gene-editing-treatments">told</a> Bloomberg that regulation needs to evolve as science develops. Prasad reportedly added that scientific advances like Nobel prize-winning CRISPR gene-editing technology have forced the agency to relax some of its strict rules.The agency is “going to be extremely flexible and work very fast with the scientists who want to bring these therapies to kids who need it,” Prasad told Bloomberg.The executive is reportedly set to publish a paper in early November detailing the FDA’s new approach. Prasad expects it will spark interest in developing treatment for rare diseases.<h2 class="st-heading-2">CRISPR’s Potential</h2>CRISPR gene editing is a technology that allows scientists to modify an organism's DNA precisely. It involves a guide RNA that directs a DNA-cutting enzyme to a specific target in the DNA for it to make a cut. The cell's natural repair process either inactivates the gene or allows scientists to insert a new piece of DNA.Earlier this year, an infant named KJ Muldoon, born with a rare genetic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, was successfully treated with a customized CRISPR gene editing therapy by a team at the Children’s Hospital of Philadelphia.The team behind the treatment of the infant is now designing clinical trials that can be used to gain FDA approval with a gene-editing platform that can be tailored for patients with different genetic mutations, Bloomberg reported. The team is asking for FDA permission to start clinical trials for a liver disorder known as phenylketonuria and urea cycle disorders, the report added.These diseases can be treated by editing genes in the liver, a known target for CRISPR, team members told Bloomberg.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ardelyx-shares-soar-premarket-as-ceo-sees-continued-demand-for-blockbuster-drug-ibsrela/cLGqRUcR3Ur">Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA To Ease Review Process For Life-Saving Gene-Editing Therapies: Report

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 

Equity

Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies. 


UnitedHealth Lifts EPS Outlook Despite Mixed Q3 Results: ETFs in Focus

UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV. 

Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs

Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs. 

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

President Donald Trump on Monday called on the Democrats to end the government shutdown, which is now in its sixth day, while also expressing his willingness to negotiate with them on healthcare, the key sticking point.In a Truth Social post, Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115329671584864920">said</a>, “Democrats have SHUT DOWN the United States Government right in the midst of one of the most successful Economies, including a Record Stock Market, that our Country has ever had.” The president lamented that this has affected several programs, services and other things the Americans rely on, adding that “It should not have happened.After the Republicans and Democrats could not agree on a stopgap funding deal, the government has been shut down since the start of the fiscal year (October 1). In a report released last Wednesday, Morgan Stanley strategists stated that the possibility of permanent layoffs among federal workers, as well as delays in economic reports, could make the first shutdown in six years more consequential than previous instances.Notwithstanding the headwind, the stock market has been on a tear, clocking fresh highs in a trot. On Monday, all the major stock market gauges closed at fresh records, thanks to the boost provided by artificial intelligence (AI) news flow.For the year-to-date (YTD) period, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> have gained 15.6% and 19.3%, respectively. On Stocktwits, retail traders remained cautious, with the sentiment toward both the SPY and QQQ ETF remaining ‘bearish’ by late Monday. The message volume on the SPY stream remained ‘high,’ while that on the QQQ was at ‘normal’ levels.&nbsp;In his post, Trump said, “I am happy to work with the Democrats on their Failed Healthcare Policies, or anything else, but first they must allow our Government to reopen. In fact, they should open our Government tonight!”The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire. The expiration of healthcare funding would result in a sharp spike in the healthcare premiums Americans pay. Meanwhile, the Republicans want a plan to keep the government funded until Nov. 21 and negotiate spending policy only through the regular funding process.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a>, which is up about 5.4% YTD, attracted ‘neutral’ sentiment, a deterioration from the ‘bullish’ mood seen the day before, but the message volume stayed ‘high.’Earlier in the day, while talking to reporters in the Oval Office, Trump said, “We have a negotiation going on right now with the Democrats that could lead to very good things. And I’m talking about good things with regard to health care, the Hill <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://thehill.com/policy/healthcare/5541610-trump-democrats-healthcare-deal/">reported.</a> When asked if the Affordable Care Act (ACA), aka Obamacare Act, subsidies would be extended, the president said, “If we made the right deal, I’d make a deal. Sure.”“You have subsidies, that’s the problem with ObamaCare. The subsidies are so much, it’s billions and billions of dollars is being wasted. And we could have a much better health care than we have right now. And we’re talking to them. I’m not saying that’s going to happen.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-vouches-for-microsoft-cloud-growth-with-675-price-target/ch6RQDgR3gw">Wells Fargo Vouches For Microsoft Cloud Growth With $675 Price Target On Stock</a>

U.S. President Donald Trump speaks in the Oval Office at the White House on October 06, 2025 in Washington, DC. 

Trump Says He's 'Happy To Work' With Democrats On 'Failed' Healthcare Policies, But Calls To End Government Shutdown 

The failure to clinch a funding deal is primarily due to the Democrats’ insistence on extending healthcare funding, mainly the Obamacare subsidies that are set to expire.

The looming&nbsp;U.S. government shutdown is seen as a significant headline risk for the market, which has been on an extended bull run. An absence of a deal&nbsp;regarding government funding among lawmakers by Sept. 30, when the fiscal year ends, could result in massive layoffs, further complicating the economic outlook.The standoff concerns a plan for discretionary funding for the upcoming fiscal year. On Sept. 19, a stopgap bill to fund the government through Nov. 21 failed to clear the Senate, where it needed 60 votes, after the Republican-controlled House passed it.An ongoing Stocktwits poll,&nbsp;in partnership with Polymarket, which asked platform users if the U.S. government would shut down this year, found that opinions were split equally. While 51% of the respondents said it&nbsp;was unlikely, 48% said it&nbsp;was likely to occur.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_12_08_AM_png_a52535d339.webp" alt="Screenshot 2025-09-29 at 2.12.08 AM.png">According to Polymarket, Stocktwits’ predictions market partner, the odds of a government shutdown have decreased to 72% from 80% as of Friday. The improved odds reflected optimism after reports, citing a White House official,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-meet-top-congressional-leaders-monday-white-house-official-says-2025-09-28/">stated</a> that President Donald Trump would meet with top lawmakers from both sides of the aisle on Monday to discuss government funding and avert a shutdown. Incidentally, the president cancelled a previous meeting with Rep. Hakeem Jeffries (D-N.Y.) and Sen. Chuck Schumer (D-N.Y.) to discuss the issue.&nbsp;The main area of contention is the Affordable Care Act tax credit subsidies, which are set to expire by the end of the year. While Democrats are fixated on discussing an extension as part of the negotiations, their Republican counterparts believe there is still time to address the issue.In his preview of the week ahead, economist Mohamed El-Erian said, “All eyes will be on Washington as the U.S. Congress attempts to iterate toward an agreement to avoid a government shutdown,”&nbsp;adding that&nbsp;much depends on the ongoing negotiations between the Trump Administration and Congressional leaders.In a joint statement, Democratic leaders Jefferies and Schumer confirmed Monday’s meeting with Trump and expressed their willingness to help resolve the crisis. “We are resolute in our determination to avoid a government shutdown and address the Republican healthcare crisis,” they said.The stock market has been chugging along nicely despite the multiple headwinds the economy is facing. The major indices trade just shy of their records, with the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund (ETF) that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> having risen 14% and 17%, respectively, year-to-date.On Stocktwits, sentiment toward both ETFs was ‘neutral’ as of early Monday, while the message volume on both streams remained at ‘high’ levels. The&nbsp;<a href="https://stocktwits.com/symbol/IYH">iShares U.S. Healthcare ETF (IYH)</a> is down 1% this year.&nbsp;Economists and market participants are mainly worried about the shutdown as investors close out the month and quarter, according to a MarketWatch <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/the-last-thing-the-stock-market-wants-right-now-is-a-government-shutdown-heres-why-7bac216e?mod=home_lead">report.</a> Charles Schwab investment strategist Kevin Gordon reportedly said, “This one could come at a really unfortunate time because we are supposed to get the jobs report on Friday,” adding that “If we don’t get access to that data, it’s going to be a problem.”The report also stated that Wells Fargo Global Strategist Gary Schlossberg said, “At the moment, we view the government shutdown on Oct. 1 as a high-probability event, likely lasting long enough to delay release of the September jobs [report] and, likely, CPI releases, due out October 3 and 15, respectively.”He sees any shutdown now as causing more extensive disruptions to data releases than the partial shutdown that occurred between December 2018 and January 2019 because more agencies are poised to be impacted by the lack of appropriation bills passed by Congress.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-s-paul-atkins-signals-fast-track-for-trump-plan-not-retreat-from-transparency/chDMru6R37X">Goodbye Quarterly Earnings? SEC’s Paul Atkins Signals Fast-Track For Trump Plan But Says It’s ‘Not A Retreat From Transparency’</a>

Tourists walk through the Rotunda in the U.S. Capitol Building on September 23, 2025 in Washington, DC. 

Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.

US Government Shutdown Risk Splits Retail Traders — Strategists Warn Key Jobs Report Could Be Delayed

The standoff concerns a plan for discretionary funding for the upcoming fiscal year.


A White House official reportedly said on Friday that countries with existing trade agreements with the U.S. would be exempt from the recently announced pharmaceutical tariffs.&nbsp;According to a Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/news/reuters.com,2025:newsml_S0N3U402V:0-latest-drug-tariffs-don-t-apply-to-nations-with-trade-deals-white-house-says/">cited</a> by TradingView, when asked whether pharmaceutical tariffs would apply to trading partners such as the European Union and Japan, which already have trade deals, the official stated that the Trump administration would honor the 15% cap as part of those pacts. Other nations with U.S. trade deals include Vietnam, the U.K., Indonesia, and the Philippines. Major partners like India, Canada, and Mexico have yet to finalize&nbsp;an agreement.The clarification comes after President Donald Trump on Thursday announced a 100% tariff on imported, branded, and patented pharmaceutical drugs starting October 1. In his Truth Social&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/115267512131958759">post</a> announcing the tariffs, Trump only highlighted that an exception would be made for any company that is “IS BUILDING their Pharmaceutical Manufacturing Plant in America.” He explained that “is building” refers to “‘breaking ground’ and/or ‘under construction’.”In a note to investors on Friday morning, Jefferies analyst Akash Tewari described the new pharmaceutical tariffs as "a win for Pharma" and "a light at the end of the Trump tunnel," noting that several large-cap companies have already announced U.S. manufacturing projects. Tewari suggested the tariffs and the MFN pilot program may serve as a symbolic “on paper” win ahead of midterms, with limited material impact on pharmaceutical companies.The 100% tariff is higher than what Trump had indicated in August.&nbsp; He&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">stated</a> that tariffs would be increased over time, allowing companies sufficient time to build factories and relocate production. Trump had said he would start by charging a “small tariff” on pharmaceuticals and raise the rate over a year or more to 150% and even 250%.The&nbsp;<a href="https://stocktwits.com/symbol/IHE">iShares U.S. Pharmaceuticals ETF (IHE)</a> edged 1.3% higher in midday trade. On Stocktwits, retail sentiment around the ETF improved to ‘neutral’ from ‘bearish over the past day. Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rose 0.86% with retail sentiment trending in ‘bullish’ territory as chatter rose to ‘high’ from ‘normal’ levels.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pce-report-core-inflation-holds-steady-at-2-9-in-august/chDViYeR3eE">PCE Report: Core Inflation Holds Steady At 2.9% In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report

According to a Reuters report cited by TradingView, a White House official stated that the Trump administration will honor the 15% pharmaceutical tariff cap for trade partners such as the EU and Japan, as outlined in existing agreements.

BlackRock Institutional Trust Company N.A. - iShares U.S. Healthcare ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

IYH
iShares US Healthcare ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IYH News

IYHiShares US Healthcare ETF